Familial short stature (FSS) is a genetic disorder characterized by short stature within a family, with growth parameters below the 3rd percentile for the corresponding age and sex cohort. FSS includes a group of hereditary disorders that are usually not accompanied by other somatic or endocrine pathologies, such as growth hormone deficiency or other diseases that lead to impaired normal growth. The underlying mechanism that causes this disorder is genetic predisposition, with most forms of the disease inherited in an autosomal recessive manner. It is important to note that FSS is not usually a sign of any systemic disease, and children with this condition often have normal physical and mental development.
History of the disease and interesting historical facts
Familial short stature was first described in the medical literature in the early 20th century. At that time, it was believed that short stature in families could be genetically transmitted rather than caused by any disease. The most notable studies conducted in the following decades demonstrated that short stature could be a stable trait, transmitted from generation to generation. Also interesting is the fact that recent genetic studies have identified specific chromosomal loci associated with short stature. This advance has opened new horizons in understanding the mechanism of the disease and its possible therapeutic options.
Epidemiology
According to current epidemiological data, the prevalence of familial short stature varies across populations. Estimates suggest that FSS may occur in 1-2% populations, with the frequency increasing depending on ethnicity and regional factors. Studies in Europe and North America suggest a significant predominance of cases in families with short stature, while FSS is less common in populations with high average stature. It is important to note that potential underestimation of FSS cases may be due to the disorder being confused with other forms of growth failure.
Genetic predisposition to this disease
The genetic basis of familial short stature involves multiple genes, including but not limited to loci on chromosomes 3, 12, and 17. In particular, studies have identified mutations in genes responsible for growth regulation and cell division. One of the most studied is the SHOX (short stature homeobox gene), located on the X chromosome, which plays a key role in normal bone and cartilage growth. Other genes, such as IGF1 and IGF1R, are also associated with height and may show mutations in patients with FSS. According to current research, it is also suggested that family analysis and genetic testing may be useful in identifying the specific mutation and the possibility of its transmission to future generations.
Risk factors for the development of this disease
Risk factors that contribute to the development of familial short stature include both physical and chemical aspects. These include:
- Hereditary predisposition from parents to short stature;
- Environmental factors such as poor nutrition and vitamin deficiency in childhood;
- Toxic exposure (eg, drinking alcohol or smoking during pregnancy);
- Endocrine disorders, although weakly associated with FSS;
- Chronic diseases that can lead to secondary short stature.
Thus, FSS is usually a consequence of genetic inheritance, but can also be influenced by external factors.
Diagnosis of this disease
Diagnosis of familial short stature is based on clinical data and laboratory tests. The main symptoms indicating the presence of this disease include:
- Low growth compared to same-age peers;
- Absence of other physical ailments;
- Normal development and no deviations in psychomotor development.
Laboratory tests may include growth hormone levels, IGF-1, and other related parameters. Radiological tests, such as X-rays, can assess the age of bone development and identify possible abnormalities. Differential diagnosis is important to rule out other forms of short stature, such as Laron syndrome or growth hormone deficiency.
Treatment
General treatment of familial short stature usually does not require specific interventions other than proper nutrition and physical activity to ensure normal growth of children. Pharmacological treatment is not used in most cases, as FSS is not considered a disease requiring treatment. Surgery is also not necessary unless there are other associated diseases or growth defects. However, in some cases, doctors may recommend hormonal treatment if there is a possibility of improving growth. Other therapies may include consultations with nutritionists and psychologists to improve the general well-being and self-confidence of children.
List of medications used to treat this disease
So, if therapy is necessary, the pharmacological agents used may include:
- Growth hormone (recombinant IGF-1);
- Food supplements containing vitamins and minerals;
- Medicines for the correction of metabolic processes if necessary.
It is important to note that the use of these drugs should be carried out strictly according to indications and under the supervision of a physician.
Disease monitoring
Monitoring of familial short stature is organized through regular examinations by pediatricians and endocrinologists, who should monitor growth and development parameters. The prognosis in most cases is favorable, and most children with FSS reach a full adult life. However, potential complications may include problems with self-esteem, especially in adolescence, and possible psychological difficulties. Regular monitoring allows parents and doctors to promptly respond to any changes and maintain the child's health at an optimal level.
Age-related features of the disease
Familial short stature can manifest itself in different age groups, starting in early childhood and continuing into adolescence. In early childhood, children usually have normal physical development, but with age, the growth rate slows down. In adolescents, short stature can cause an inferiority complex and affect socialization. Therefore, it is important to maintain a positive image and self-confidence in adolescents. Adults with a history of FSS usually have compensatory mechanisms and can successfully adapt to society.
Questions and Answers
- What are the main symptoms of familial short stature?
The main symptoms include short stature compared to standard indicators for age, the absence of diseases that contribute to short stature, and otherwise normal development. - Is it possible to treat familial short stature?
Since familial short stature is not considered a medical condition, no specific treatment is needed. However, hormonal treatment may sometimes be recommended to improve growth. - What is the genetic nature of this condition?
Genetic predisposition plays a key role in FSS, and several genes involved in the development of the disease have been identified. - How is familial short stature diagnosed?
Diagnosis includes a clinical examination, laboratory tests, radiography to assess bone age and rule out other diseases. - What is the prognosis for this disease?
The prognosis is generally good, and most children reach full adulthood without significant health problems.
Dr. Oleg Korzhikov offers some advice for patients and their parents who are faced with familial short stature:
— Stay positive and support your child’s self-confidence. It is important to create an environment where the child can feel comfortable and accept themselves.
— Consult a specialist if you have any concerns or questions regarding growth – early diagnosis can help optimize development.
— Monitor your child’s diet. A balanced diet can promote normal development.
— Discuss any concerns about growth with your children so they can openly share their feelings and concerns.
